BLAU3 Stock Overview
A pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Blau Farmacêutica S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$14.24 |
| 52 Week High | R$17.73 |
| 52 Week Low | R$9.20 |
| Beta | 0.45 |
| 11 Month Change | 19.36% |
| 3 Month Change | 42.54% |
| 1 Year Change | -14.73% |
| 33 Year Change | -70.29% |
| 5 Year Change | n/a |
| Change since IPO | -65.35% |
Recent News & Updates
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings
Aug 29
Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?
Jun 28Recent updates
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings
Aug 29Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?
Jun 28Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop
Feb 01What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates
May 14Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Feb 24Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely
Oct 14Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)
Aug 17Shareholder Returns
| BLAU3 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0.6% | 1.6% | -0.6% |
| 1Y | -14.7% | 8.2% | 7.1% |
Return vs Industry: BLAU3 underperformed the BR Biotechs industry which returned 8.2% over the past year.
Return vs Market: BLAU3 underperformed the BR Market which returned 7.1% over the past year.
Price Volatility
| BLAU3 volatility | |
|---|---|
| BLAU3 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in BR Market | 9.3% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: BLAU3's share price has been volatile over the past 3 months.
Volatility Over Time: BLAU3's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,900 | Marcelo Hahn | www.blau.com |
Blau Farmacêutica S.A., a pharmaceutical company provides high-complpexity drugs in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its medications cover various segments, such as immunology, hematology, oncology, nephrology, infectious diseases, anesthesiology, and others. The company provides uterine stimulator; anesthetics; feminine health care; oncological products; antivirals and antiretrovirals; acid pump inhibitor; antithrombotic; antirheumatic; antibiotics; biopharmaceuticals; essential hospital products; biosimilars; hemoderivatives; and thrombolytics.
Blau Farmacêutica S.A. Fundamentals Summary
| BLAU3 fundamental statistics | |
|---|---|
| Market cap | R$2.43b |
| Earnings (TTM) | R$217.68m |
| Revenue (TTM) | R$1.57b |
11.6x
P/E Ratio1.6x
P/S RatioIs BLAU3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLAU3 income statement (TTM) | |
|---|---|
| Revenue | R$1.57b |
| Cost of Revenue | R$1.05b |
| Gross Profit | R$520.57m |
| Other Expenses | R$302.89m |
| Earnings | R$217.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 05, 2024
| Earnings per share (EPS) | 1.23 |
| Gross Margin | 33.05% |
| Net Profit Margin | 13.82% |
| Debt/Equity Ratio | 25.5% |
How did BLAU3 perform over the long term?
See historical performance and comparison